Výsledky vyhledávání - "Bart Schreuder"

Akademický článek

Shared decision making in primary malignant bone tumour surgery in children and young adults

Autor: Kiki Blom, Peter Bekkering, Marlieke Hagemeijer, Marta Fiocco, Gerard Schaap, Michiel van de Sande, Sander Dijkstra, Bart Schreuder, Ingrid van der Geest, Paul Jutte, Joris Ploegmakers, Hans Merks, Jos A.M. Bramer

Publikováno v: EJC Paediatric Oncology, Vol 3, Iss , Pp 100138- (2024)

Background: Children and young adults needing surgery for a primary malignant bone tumour around the knee face a difficult, life changing decision. This study describes the level of shared decision making (SDM) experienced and preferred by these pati

Externí odkaz: https://doaj.org/article/4c19eb1b8e5a4617bfbdc56994355b11

Zobrazit plný text záznamu

Akademický článek

Can MRI differentiate between atypical cartilaginous tumors and high-grade chondrosarcoma? A systematic review

Autor: Claudia Deckers, Maarten J Steyvers, Gerjon Hannink, H W Bart Schreuder, Jacky W J de Rooy, Ingrid C M Van Der Geest

Publikováno v: Acta Orthopaedica, Vol 91, Iss 4, Pp 471-478 (2020)

Background and purpose — Adequate staging of chondroid tumors at diagnosis is important as it determines both treatment and outcome. This systematic review provides an overview of MRI criteria used to differentiate between atypical cartilaginous tu

Externí odkaz: https://doaj.org/article/52a080b387be47ed8dcc97b7d2b08bb5

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities

Autor: Evelien G. E. Hurkmans, Marije J. Klumpers, Sita H. Vermeulen, Melanie M. Hagleitner, Uta Flucke, H. W. Bart Schreuder, Hans Gelderblom, Johannes Bras, Henk-Jan Guchelaar, Marieke J. H. Coenen, D. Maroeska W. M. te Loo

Publikováno v: Frontiers in Pharmacology, Vol 11 (2020)

High-dose methotrexate is a cornerstone agent in the chemotherapeutic treatment of patients with osteosarcoma. However, patients often develop methotrexate-induced toxicities. We aim to identify determinants of methotrexate-induced toxicities in oste

Externí odkaz: https://doaj.org/article/c702ae5dc3b84a2bb86d47681b47a68d

Zobrazit plný text záznamu

Akademický článek

Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands

Autor: Monique J L Mastboom, Floortje G M Verspoor, Arjan J Verschoor, Daniël Uittenbogaard, Banne Nemeth, Walter J B Mastboom, Judith V M G Bovée, P D Sander Dijkstra, H W Bart Schreuder, Hans Gelderblom, Michiel A J Van de Sande, TGCT study group

Publikováno v: Acta Orthopaedica, Vol 88, Iss 6, Pp 688-694 (2017)

Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current

Externí odkaz: https://doaj.org/article/bd0c8dae8e894cfeb93551fb71765cac

Zobrazit plný text záznamu

Plný text ve formátu HTML

Supplementary Table 3 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Autor: Dunja M.W.M te Loo, Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Frank N. van Leeuwen, Uta Flucke, H.W. Bart Schreuder, Winette T.A. van der Graaf, Eveline S.J.M. de Bont, Hanneke I. Vos, Remco R. Makkinje, Hans Gelderblom, Marieke J.H. Coenen, Melanie M. Hagleitner

Supplementary Table 3. Genetic variants associated with 5-year PFS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373af66ca7e1657a72c7d47c2e65c4f8
https://doi.org/10.1158/1078-0432.22454916

Zobrazit plný text záznamu

Supplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Supplementary Table 2. Genetic variants associated with histologic response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7425f23f113b4c402bb1214257e49f1f
https://doi.org/10.1158/1078-0432.22454919

Zobrazit plný text záznamu

Data from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Purpose: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy is the dominant risk factor for poor survival. Pharmacogenetic research can offer possibilities to optimize treatment and improve outcome. We applied a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20536c0c0ae4a3cf902db4fbfba75548
https://doi.org/10.1158/1078-0432.c.6522873

Zobrazit plný text záznamu

Supplementary Table 1 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Supplementary Table 1. Set of 381 SNPs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70abd06bb2871ef7ba9f30af68e6fad6
https://doi.org/10.1158/1078-0432.22454922.v1

Zobrazit plný text záznamu

Akademický článek

Arthroplasty for tenosynovial giant cell tumors: 17 patients followed for 0.2 to 15 years

Autor: Floortje G M Verspoor, Gerjon Hannink, Anouk Scholte, Ingrid C M Van Der Geest, H W Bart Schreuder

Publikováno v: Acta Orthopaedica, Vol 87, Iss 5, Pp 497-503 (2016)

Background and purpose — Tenosynovial giant cell tumors (t-GCTs) can behave aggressively locally and affect joint function and quality of life. The role of arthroplasty in the treatment of t-GCT is uncertain. We report the results of arthroplasty i

Externí odkaz: https://doaj.org/article/8238cca1ff5742128b534790da6147be

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání